Skip to main content
. 2002 Dec 9;99(26):16636–16641. doi: 10.1073/pnas.252643699

Fig 4.

Fig 4.

Induction of hPNPaseold-35 mRNA by IFNs in various cell types. (A) Time-course treatment of HO-1 cells with IFN-β (2,000 units/ml). (B) IFN-β dose response in HO-1 cells. Cells were untreated (U) or treated with 0.1–2,000 units/ml for 7 h. (C) Treatment of HO-1 cells with different cytokines for 17 h. U, untreated; Iα, IFN-α (1,000 units/ml); Iβ, IFN-β (1,000 units/ml); Iγ, IFN-γ (1,000 units/ml); TNF-α, tumor necrosis factor α (10 ng/ml). (D) Effect of IFN-β and poly(I)·poly(C) treatment on hPNPaseold-35 and gapdh expression in HO-1 cells. U, untreated or treated for 24 h with IFN-β (2,000 units/ml), poly(I)·poly(C), 1× (10 μg/ml), or 2× (20 μg/ml). (E) Analysis of hPNPaseold-35 and gapdh expression in various human melanomas without (−) or with (+) IFN-β (2,000 units/ml) treatment for 18 h. (F) Analysis of hPNPaseold-35 and gapdh expression in human breast carcinoma (MDA-MB-157, MDA-MB-231, and MCF-7) or human osteosarcoma (Saos2) cells without (−) or with (+) IFN-β (2,000 units/ml) treatment for 18 h. A lower quantity of RNA is present in the untreated versus the treated WM238 sample.